{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:21:01Z","timestamp":1775467261203,"version":"3.50.1"},"reference-count":17,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>We report the case of a man with chronic tophaceous gout who had end-stage renal failure secondary to the Alport syndrome. Following a failed kidney transplant, where urate deposition was a suspected contributor, the patient responded positively to consistent allopurinol therapy and regular haemodialysis sessions. Extensive and destructive tophi receded in size remarkably and the almost constant incidence of acute attacks of gout subsided. The patient has recently received a new kidney transplant and his plasma concentrations of urate are controlled well with allopurinol and he no longer experiences acute attacks of gout. While efficacious, adherence is critical for achieving the therapeutic effects of allopurinol even in end-stage renal disease.<\/jats:p>","DOI":"10.1136\/bcr.02.2012.5814","type":"journal-article","created":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T14:06:37Z","timestamp":1338991597000},"page":"bcr0220125814","source":"Crossref","is-referenced-by-count":9,"title":["Successful use of allopurinol in a patient on dialysis: Table 1"],"prefix":"10.1136","author":[{"given":"Richard Osborne","family":"Day","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diluk Romesh Wijekoon","family":"Kannangara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J","family":"Furlong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2012,6,6]]},"reference":[{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/26.6.445"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.2","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem246"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ki.1975.81","article-title":"An evaluation of the pathogenesis of gouty kidney","volume":"8","author":"Emmerson","year":"1975","journal-title":"Kidney Int"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh679"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.7","first-page":"498","article-title":"Gout in ambulatory care settings in the United States","volume":"35","author":"Krishnan","year":"2008","journal-title":"J Rheumatol"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.8","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.9","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00001"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5694\/j.1326-5377.1993.tb137784.x","article-title":"Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs?","volume":"159","author":"Kot","year":"1993","journal-title":"Med J Aust"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.11","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.925"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.15","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1994.1022"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.16","doi-asserted-by":"publisher","DOI":"10.1097\/00002480-196504000-00047"},{"key":"2025040405401645000_2012.jun05_1.bcr0220125814.17","first-page":"618","article-title":"Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol","volume":"54","author":"Johnson","year":"1979","journal-title":"Mayo Clin Proc"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.02.2012.5814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:01:08Z","timestamp":1743789668000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.02.2012.5814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,6]]},"references-count":17,"alternative-id":["10.1136\/bcr.02.2012.5814"],"URL":"https:\/\/doi.org\/10.1136\/bcr.02.2012.5814","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,6]]}}}